Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab plus venetoclax and azacitidine versus placebo plus venetoclax and azacitidine in untreated AML ineligible for intensive chemotherapy
NL-OMON54256Phase 3Recruiting
- Sponsor
- Gilead Sciences
- Start
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Magrolimab + venetoclax + azacitidine with Placebo + venetoclax + azacitidine (2 arms). Primary endpoint: Overall survival. Started Apr 2023; status: recruiting.
02
Drugs
magrolimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON54256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54256.